PER-048-16招募中未知
A PHASE IIB, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, DOSE-RANGING STUDY TO ASSESS THE EFFICACY AND SAFETY OF MSTT1041A IN PATIENTS WITH UNCONTROLLED SEVERE ASTHMA
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- A
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Inclusion Criteria
- •4.1.1.1 Inclusion Criteria for Enrollment in the Run-In Period
- •Patients must meet the following criteria to be eligible for enrollment in the run-in period:
- •Signed Informed Consent Form
- •Age 18−75 years at time of signing Informed Consent Form
- •Able to comply with the study protocol, in the investigator’s judgment
- •Body mass index (BMI) of 18−35 kg/m2 and weight ≥ 40 kg at screening
- •Documented physician-diagnosed asthma for at least 12 months prior to screening
- •On ICS therapy at a total daily dose ≥ 500 μg of fluticasone propionate or equivalent plus at least one additional allowed controller medication, for ≥ 3 months prior to
- •screening, with no changes within 4 weeks prior to screening or during the screening period and no anticipated changes in controller dosing regimens throughout the study
- •-Patients may receive one or more of the following additional controller medications: LABA, LTM, LAMA, or long-acting theophylline preparation.
- •Morning pre-bronchodilator FEV1 of 40%−80% of predicted at the screening and run-in (Week 0) visits
- •Post-bronchodilator reversibility of FEV1 (liters) of ≥ 12% and ≥ 200 mL at screening
- •-Patients are allowed up to three attempts to meet reversibility criteria, within the screening period (see Section 4.5.2 for details).
- •- Specific guidelines for performing and interpreting bronchodilator reversibility testing, including medication-withholding strategies and appropriate dosing of short-acting bronchodilators, will be provided to investigators.
- •Uncontrolled asthma during the screening period, defined as an ACQ-5 score ≥ 1.5 and at least one of the following symptoms of asthma that is not controlled according to EPR3 (2007) and GINA (2015) guidelines:
- •Nighttime awakening ≥ 1 time/week
- •-Use of short-acting rescue therapy > 2 days/week
- •- Documented history of at least one asthma exacerbation within 12 months prior to screening while on daily ICS maintenance therapy (same dose as at screening), defined as new or increased asthma symptoms (wheezing, coughing, dyspnea, chest tightness, and/or nighttime awakenings due to these symptoms) that result in one or both of the following:
- •-Hospitalization or emergency department or urgent care visit requiring administration of asthma treatment, such as bronchodilators and/or systemic corticosteroids, in addition to baseline controller medications
- •-Treatment with systemic corticosteroids for ≥ 3 days or a long-acting depot corticosteroid preparation with a therapeutic effectiveness of ≥ 3 days
- •Demonstrated compliance with required use of the eDiary, defined as documenting asthma controller medication use and answering questions related to asthma symptoms, nighttime awakenings due to asthma, and use of short-acting rescue therapy on 5 of 7 days during each of 2 consecutive weeks during the screening period (see Section 4.5.5.2 and Section 4.5.5.3 for details)
- •Demonstrated compliance with required PEFR measurements, defined as measuring PEFR on 5 of 7 days during each of 2 consecutive weeks during the screening period (see Section 4.5.5.1 for details)
- •Demonstrated adherence with usual asthma controller medication regimen, defined as patients responding affirmatively that they have taken their asthma controller medications on 5 of 7 days during each of 2 consecutive
排除标准
- •+ Exclusion Criteria for Enrollment in the Run-In Period:
- •Patients who meet any of the following criteria will be excluded from enrollment in the
- •run-in period:
- •Diagnosis of vocal cord dysfunction, reactive airways dysfunction syndrome, hyperventilation associated with panic attacks, or other mimics of asthma
- •Diagnosis of occupational asthma, aspirin-sensitive asthma, asthma−chronic obstructive pulmonary disease (COPD) overlap syndrome, or bronchiolitis, as determined by the investigator
- •Pregnant or lactating, or intending to become pregnant during the study or within 20 weeks after the last dose of MSTT1041A
- •-Women of childbearing potential must have a negative serum pregnancy test result during the screening period.
- •History of smoking (tobacco or marijuana) or vaping within 6 months prior to screening, significant smoking history (defined as ≥ 10 pack-years), or unwilling to abstain from smoking from the time of consent through the completion of the study
- •-A pack-year is defined as the average number of packs of cigarettes per day times the number of years of smoking
- •History or evidence of substance abuse that would pose a risk to patient safety, interfere with the conduct of the study, have an impact on the study results, or affect the patient´s ability to participate in the study, in the opinion of the investigator
- •History or evidence of a medical condition or any clinically significant disorder, condition, or disease (e.g., psychiatric or other mental health disorder, renal failure, coronary artery disease, cardiomyopathy, heart failure, hypertension, liver disease, diabetes, anemia) that is uncontrolled despite treatment or that is likely, in the opinion of the investigator, to require a change in therapy, pose a risk to patient safety, interfere with the conduct of the study, have an impact on the study results, or affect the patient´s ability to participate in the study
- •-Patients with well-controlled comorbid disease on a stable treatment regimen for 4 weeks prior to screening are eligible for the study.
- •Myocardial infarction, unstable angina pectoris, or stroke within 12 months prior to screening
- •Any finding on the screening ECG that requires further cardiovascular evaluation (such as evidence of prior myocardial infarction, cardiomyopathy, or substantial left or right ventricular hypertrophy), in the opinion of the investigator
- •QT interval corrected using Fridericia’s formula (QTcF) > 440 ms demonstrated by at least two ECGs > 30 minutes apart
- •History of ventricular dysrhythmias or risk factors for ventricular dysrhythmias such as structural heart disease (e.g., left ventricular systolic dysfunction, left ventricular hypertrophy), coronary heart disease, clinically significant electrolyte abnormalities (e.g., hypokalemia, hypomagnesemia, hypocalcemia), or family history of sudden unexplained death or long QT syndrome
- •Current treatment with medications that are well known to prolong the QT interval • Evidence of active liver disease, including jaundice or AST, ALT, total bilirubin, or alkaline phosphatase > 2 × upper limit of normal (ULN)
- •Acute infection requiring either surgical intervention (e.g., drainage) or medical therapy (e.g., antibiotics) within 4 weeks prior to screening
- •Helminthic parasitic infection diagnosed within 6 months prior to screening that has not been treated or has not responded to standard-o
研究者
相似试验
进行中（未招募）
不适用
Treatment of Adult Allergic Asthma Patients with MEMP1972AAllergic AsthmaEUCTR2011-003997-10-HUGENENTECH, Inc.560
进行中（未招募）
不适用
Treatment of Adult Allergic Asthma Patients with MEMP1972AMedDRA version: 17.0Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersAllergic AsthmaEUCTR2011-003997-10-BGGENENTECH, Inc.560
未知
不适用
A PHASE IIB, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY AND DOSING REGIMENS OF MEMP 1972A IN ADULTS WITH ALLERGIC ASTHMA WHO ARE INADEQUATELY CONTROLLED ON INHALED CORTICOSTEROIDS AND A SECOND CONTROLLER (COSTA)PER-079-12GENENTECH, INC.,55
进行中（未招募）
1 期
A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants with Early Parkinson's DiseaseEarly Parkinson's diseaseMedDRA version: 20.0Level: PTClassification code 10061536Term: Parkinson's diseaseSystem Organ Class: 10029205 - Nervous system disordersEUCTR2020-004997-23-ATF. Hoffmann-La Roche Ltd575
进行中（未招募）
1 期
A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants with Early Parkinson's DiseaseEarly Parkinson's diseaseMedDRA version: 20.0Level: PTClassification code 10061536Term: Parkinson's diseaseSystem Organ Class: 10029205 - Nervous system disordersEUCTR2020-004997-23-ESRoche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd575